WO2014084508A1 - 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 - Google Patents
단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 Download PDFInfo
- Publication number
- WO2014084508A1 WO2014084508A1 PCT/KR2013/009474 KR2013009474W WO2014084508A1 WO 2014084508 A1 WO2014084508 A1 WO 2014084508A1 KR 2013009474 W KR2013009474 W KR 2013009474W WO 2014084508 A1 WO2014084508 A1 WO 2014084508A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- protein
- fusion protein
- domain
- aggregation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 112
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 68
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 68
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 64
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 64
- 230000000087 stabilizing effect Effects 0.000 title claims abstract description 27
- 230000002776 aggregation Effects 0.000 claims abstract description 91
- 238000004220 aggregation Methods 0.000 claims abstract description 89
- 150000003863 ammonium salts Chemical class 0.000 claims abstract description 45
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 20
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical group [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 120
- 235000019270 ammonium chloride Nutrition 0.000 claims description 60
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 40
- 239000000872 buffer Substances 0.000 claims description 29
- 229930006000 Sucrose Natural products 0.000 claims description 28
- 239000005720 sucrose Substances 0.000 claims description 28
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 26
- 239000004472 Lysine Substances 0.000 claims description 20
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 15
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 15
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 206010003246 arthritis Diseases 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 7
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 5
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 5
- 239000001099 ammonium carbonate Substances 0.000 claims description 5
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 5
- 150000008163 sugars Chemical class 0.000 claims description 5
- 125000000185 sucrose group Chemical group 0.000 claims 3
- 108091006020 Fc-tagged proteins Proteins 0.000 abstract description 8
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 55
- 108010008165 Etanercept Proteins 0.000 description 36
- 229960000403 etanercept Drugs 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 27
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 25
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 24
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 24
- 239000004475 Arginine Substances 0.000 description 22
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000000243 solution Substances 0.000 description 12
- 229920001213 Polysorbate 20 Polymers 0.000 description 11
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 11
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 11
- 229940068977 polysorbate 20 Drugs 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 239000001488 sodium phosphate Substances 0.000 description 10
- 229910000162 sodium phosphate Inorganic materials 0.000 description 10
- 229940074404 sodium succinate Drugs 0.000 description 10
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 10
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- DUMIASQJCCZABP-UHFFFAOYSA-N butanedioic acid;sodium Chemical compound [Na].OC(=O)CCC(O)=O DUMIASQJCCZABP-UHFFFAOYSA-N 0.000 description 9
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 229940073621 enbrel Drugs 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 230000004845 protein aggregation Effects 0.000 description 6
- 239000008362 succinate buffer Substances 0.000 description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 238000005054 agglomeration Methods 0.000 description 4
- 230000002744 anti-aggregatory effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 4
- 229950008882 polysorbate Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 125000001165 hydrophobic group Chemical group 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000003890 succinate salts Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102100031939 Erythropoietin Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- -1 insulinultropin Proteins 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101100306202 Escherichia coli (strain K12) rpoB gene Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 102000003959 Lymphotoxin-beta Human genes 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 101100306001 Mus musculus Mst1r gene Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- SATZVFKUEAMFPB-UHFFFAOYSA-N azanium;sodium;chloride Chemical compound [NH4+].[Na].[Cl-] SATZVFKUEAMFPB-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- IRXBNHGNHKNOJI-UHFFFAOYSA-N butanedioyl dichloride Chemical group ClC(=O)CCC(Cl)=O IRXBNHGNHKNOJI-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007076 release of cytoplasmic sequestered NF-kappaB Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01C—AMMONIA; CYANOGEN; COMPOUNDS THEREOF
- C01C1/00—Ammonia; Compounds thereof
- C01C1/16—Halides of ammonium
- C01C1/164—Ammonium chloride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
- C09K15/20—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen and oxygen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention relates to a composition for stabilizing a fusion protein of a protein having a physiological activity and an Fc domain, and to a method for stabilizing a fusion protein of a protein and an Fc domain using a composition containing an ammonium salt or an ammonium salt and succinate. It is about.
- Antibody drugs which are used for the treatment of diseases, are biopharmaceuticals with high-level bioprocessing technology such as cell line production technology, cell culture technology, and purification technology.
- a fusion protein (TNFR: Fc etanercept) prepared by fusing an extracellular ligand binding portion of a human p75 tumor necrosis factor receptor to the Fc domain of human IgG1 is used to treat rheumatoid arthritis.
- TNFR Fc etanercept
- Regulatory peptide, 170, 2011 have attempted to increase the half-life in the body by fusing physiologically active substances such as hGH and EPO to the Fc domain (KR10-2008-7018012).
- a substance that binds to the domain has been used as a drug for the treatment of wet macular degeneration (WAMD).
- a fusion protein has a problem in that its structure is large and complex, forming an aggregation caused by physical instability. Factors causing such aggregation exist in various ways during the production and storage of proteins.
- aggregation may occur due to one or more of the following factors.
- pH, salt type, salt concentration, temperature, contact with air, stirring speed, etc. which are not optimal conditions, may be affected, and the concentration condition of the protein may be influenced when formulated.
- the passage of the filter and agitation may affect the buffer exchange, and during storage, temperature change, pH change, contact with air, and agitation may affect the aggregation phenomenon.
- agglomeration may occur when the formulation containing the protein is exposed to light, and the material of the packaging container may also cause agglomeration (Hamada, H. et al., Current Pharmaceutical Biotechnology , 10: 400). , 2009).
- the main cause of the aggregation phenomenon in buffer fusion proteins occurs when the hydrophobic sites of the antibody protein are exposed due to structural changes.
- the aggregation of the hydrophobic sites of the protein molecules to form agglomerates, the coagulation formed in this way may occur in an irreversible form covalent bond between the antibody proteins (Hamada, H. et al., Current Pharmaceutical Biotechnology , 10: 348 , 2009).
- aggregated fusion proteins or antibody proteins generally have reduced activity or lose activity over time.
- these proteins when these proteins are aggregated, they have antigenicity that was not shown in the non-aggregated state, and when injected into the human body, they may cause the production of antibodies (antidrug antibodies, ADA). Therefore, there is an urgent need for a method for reducing such aggregation of fusion proteins and for a stable formulation of fusion proteins with reduced levels of aggregation (Current Trends in Monoclonal Antibody Development and Manufacturing, Biotechnology: Pharmaceutical Aspects Volume XI, 2010, pp 271-291).
- Amphiphilic polymers such as, for example, amino acids (US4362661A, US7648702) such as arginine, lysine, proline, histidine, glycine, polysorbate based surfactants, polyethylene glycols, polyethylene glycols (PEG) or polyvinylpyrrolidone (PVP) Polysaccharides such as dextran, monosaccharides or disaccharides (US5945098A) such as sucrose, maltose and trehalose are used.
- amino acids such as arginine, lysine, proline, histidine, glycine
- PEG polyethylene glycols
- PVP polyvinylpyrrolidone
- Polysaccharides such as dextran, monosaccharides or disaccharides (US5945098A) such as sucrose, maltose and trehalose are used.
- the stability thereof is generally lower than that of the produced antibody protein, so that a tendency to form aggregates is stronger than that of other proteins or antibody proteins.
- a surfactant such as polysorbate
- the present inventors have confirmed that the composition containing ammonium salt or ammonium salt and succinate can increase its stability to facilitate long-term storage by inhibiting aggregation of the protein and the fusion protein of the Fc domain, and the present invention To complete.
- An object of the present invention is to provide a stabilizing composition capable of increasing the stability of a fusion protein by inhibiting aggregation of a protein having a physiological activity and a fusion protein of an Fc domain, and a method for stabilizing an Fc-fusion protein using such a composition. .
- Another object of the present invention to provide a composition for the prevention and treatment of diseases comprising the stabilizing composition.
- the present invention provides a composition for stabilizing the Fc-fusion protein containing the ammonium salt, or ammonium salt and succinate, and a composition for preventing and treating diseases comprising the same.
- the present invention provides a method of stabilizing the fusion protein by adding ammonium salt, or ammonium salt and succinate to the composition containing the Fc-fusion protein.
- FIG. 1 shows Etanercept (fusion protein of the water-soluble portion of the TNF receptor with the Fc domain) of various types of excipients (arginine (Arg), EDTA, glycine (Gly), histidine (His), hydroxypropylcyclodextrin (HP) Cyclodextrin), ammonium chloride, polyethylene glycol (PEG), proline (Pro), sucrose (Sucrose), trehalose (Trehalose), polysorbate 20) stored in a formulation solution containing for 1 week at 50 °C, the aggregation of etanercept This is the result of measuring the degree.
- excipients arginine (Arg), EDTA, glycine (Gly), histidine (His), hydroxypropylcyclodextrin (HP) Cyclodextrin
- Ammonium chloride ammonium chloride
- PEG polyethylene glycol
- Pro proline
- sucrose Sucrose
- Tehalose Tetra
- Figure 2 shows etanercept various excipients (arginine (Arg), proline (Pro), 50 mM ammonium chloride, 100 mM ammonium chloride, 200 mM ammonium chloride, sucrose, polysorbate 20, hydroxypropylcyclodextrin ( HPcD)) is stored in the formulation solution containing for 1 week at 50 °C after measuring the degree of aggregation of etanercept.
- Figure 3 is a result of measuring the degree of aggregation of etanercept after storage of etanercept for 4 weeks at 37 °C in a formulation containing ammonium chloride.
- Arg arginine
- AmCl ammonium chloride
- AmSul ammonium sulfate
- Am + Lys Ammonium Chloride + Lysine
- Am + EDTA Ammonium Chloride + EDTA
- 4 and 5 is a formulation solution containing etanercept for 14 days at 45 °C Arginine, ammonium chloride, ammonium sulfate, ammonium chloride and lysine, ammonium chloride and EDTA, ammonium chloride and polysorbate 20, ammonium chloride and sucrose It is the result of measuring the degree of aggregation of etanercept after storage at.
- AmSul ammonium sulfate
- Am # + Lys ammonium chloride #% + lysine
- FIG. 6 shows etanercept stored at 45 ° C. for 5 days in various buffers including sodium ammonium chloride (Sodium Phosphate, Sodium Succinate, Sodium Citrate, Histidine) It is a result of measuring the aggregation degree of etanercept after.
- sodium ammonium chloride Sodium Phosphate, Sodium Succinate, Sodium Citrate, Histidine
- Figure 7 is a result of measuring the degree of aggregation of etanercept after the composition of etanercept prepared by varying the pH of the succinic acid buffer solution containing ammonium chloride at 45 °C for 5 days.
- AmCl Ammonium Chloride
- AmCl + Lys Ammonium Chloride + Lysine
- fusion protein and protein of the Fc domain refers to a fusion protein in the form of a protein fused to the Fc domain, which is a constant region of the antibody, wherein the protein is the amino acid of several amino acids formed by peptide bonds (peptide)
- polypeptide a polypeptide is used in the same sense as an oligopeptide having a low molecular weight and a protein having a high molecular weight. Therefore, in the present invention, a “fusion protein of a protein and an Fc domain” refers to a “fusion protein of a polypeptide and an Fc domain”. Has the same meaning.
- protein is a protein or polypeptide exhibiting any physiological activity, but the type is not limited, but preferably a soluble portion of various receptors such as TNF-receptor, VEGF receptor, GLP-1 analog (GLP) -1 analog and its derivatives, flt3 ligand, CD40 ligand, erythropoietin, thrombopoietin, thrombopoietin, calcitonin, calcitonin, Fas ligand, ligand for receptor activation of NF-kappa B (RANKL), tumor necrosis Factor (TNF) -related apoptosis inducing ligand (TRAIL), thymus storoma-derived lymphopoietin, granulocyte growth promoting glycoprotein, granulocyte-macrophage growth promoting glycoprotein, mast cell growth factor, stem cell Growth factor, epidermal growth factor, RANTES, growth hormone, insulin, insulin
- the soluble portion of the receptor in the present invention means an extracellular ligand-binding domain of the receptor, or a region including an extracellular ligand-binding portion and an additional transmembrane domain. .
- Fc domain refers to the constant region of the antibody, preferably, but not limited to the Fc domain of human IgG1, IgG2, IgG3 and IgG4 as well as human IgG1 can be used, IgG1, IgG2 , May include some or all of the CH1 domain, CH2 domain, CH3 domain, hinge region of IgG3 and IgG4, and may preferably include a CH2 domain, a CH3 domain and a hinge region except for the CH1 domain. .
- the fusion protein of the protein of the present invention and the Fc domain may be prepared and obtained by a general method used in the art.
- residues other than fusion proteins may be removed through one or more processes selected, such as by centrifugation, ultrafiltration and / or chromatographic procedures.
- the present invention provides a composition for stabilizing a fusion protein of a protein and an Fc domain containing an ammonium salt.
- ammonium salt refers to a salt formed by combining ammonia and an acid, and may be represented by the general formula NH 4 X (X is a monovalent acid group).
- X is a monovalent acid group.
- ammonium chloride, ammonium sulfate, ammonium carbonate and ammonium nitrate may be used, but is not limited thereto.
- the ammonium salt may be used at a concentration of 5 to 500 mM selected from ammonium chloride, ammonium sulfate, ammonium carbonate and ammonium nitrate.
- an ammonium salt having a concentration of 12.5 to 200 mM was used, but even when a small amount of ammonium salt of 12.5 mM or less or an ammonium salt of 200 mM or more is used, there is an effect of inhibiting aggregation of the fusion protein.
- the ammonium salts of the present invention effectively inhibit aggregation of fusion proteins of polypeptides and Fc domains.
- the extracellular ligand binding portion of the human p75 tumor necrosis factor receptor is stored in an ammonium chloride or ammonium sulfate solution when the fusion protein is fused to the Fc domain of human IgG1, the fusion protein is not stored in the ammonium salt solution. Compared to that, the degree of aggregation was reduced by about 80% (Fig. 1, Fig. 2).
- the composition for stabilizing the fusion protein of the protein and the Fc domain according to the present invention may further include a succinate, the succinate contains a fusion protein of the protein and the Fc domain of the present invention
- a succinate contains a fusion protein of the protein and the Fc domain of the present invention
- the succinate is added to a concentration of 5 to 200 mM, more preferably 20 to 30 mM, as well as sodium succinate, various succinates known in the art can be used.
- the succinate buffer is adjusted to have a pH of 5.5 to 6.5, more preferably to pH 6.0 to 6.3. When the pH is less than or equal to 5.5 or more than 6.5, aggregation of the fusion protein is increased, and thus, it is preferable that the pH is within the above range.
- sodium phosphate, sodium succinate, sodium citrate, and histidine buffers are additionally added to ammonium chloride excipients that have been shown to suppress aggregation of fusion proteins.
- the formulation using sodium succinic acid as a buffer was significantly lower than the formulation using sodium phosphate as a buffer currently used in the commercial etanercept (trade name Enbrel) at pH 6.5. It was confirmed. In addition, it was confirmed that the formulation with sodium succinate exhibited better aggregation inhibition than the formulation with other buffers at pH 6.0 (FIG. 6).
- amino acids are known as substances which inhibit the aggregation of proteins, and among them, basic amino acids are excellent in role as anti-aggregation agents.
- arginine is used as an anticoagulant (US 7648702 B2)
- a formulation for stabilizing Fc modified antibodies with a combination of lysine, arginine, histidine and sugar, acid buffer and polysorbate US 20100254985 Patents have been reported.
- anionic buffers such as sugars such as trehalose, sucrose, mannitol, maltose, phosphate, and citrate.
- the surfactant is attached to the denatured and exposed hydrophobic sites of the protein to increase the solubility to prevent aggregation, typically polysorbate Muromonab, Abciximab, Rituximab, Daclizimab, Alemtuzumab, Adalimumab, Bevacizumab, Natalizumab, etc. Is used in the formulation of antibody proteins.
- At least one excipient selected from basic amino acids, sugars and surfactants may be additionally used in the composition for stabilizing the fusion protein of the protein and the Fc domain according to the present invention. have.
- arginine, lysine, histidine and the like may be used at a concentration of 1 to 50 mM, and as sugar, sucrose, trehalose, mannitol, maltose and the like at a concentration of 0.5 to 10% w / v,
- surfactant Triton, Tween, and Pluronic substances may be used at a concentration of 0.001 to 0.1% w / v, but are not limited thereto. Excipients that can be used in the art to inhibit can be used without limitation.
- the present invention provides a method of stabilizing a fusion protein of a protein and an Fc domain by adding an ammonium salt to a composition containing a fusion protein of a protein and an Fc domain, the composition further comprising succinate.
- the succinate may be added at a concentration of 5 to 200 mM in the form of a buffer of pH 5.5 to 6.5.
- the ethanercept and the protein which are commercially available arthritis therapeutics, were expressed in CHO cells, and then purified by high purity.
- the ammonium salt according to the present invention is effective in inhibiting the aggregation of the fusion protein and stabilizing the formulation thereof.
- the use of the ammonium salt according to the present invention in comparison with arginine used for preventing aggregation of etanercept products In this case, it was confirmed that the aggregation inhibitory effect of the fusion protein is more excellent (Example 2).
- the present invention provides a composition for treating arthritis, containing a fusion protein and an ammonium salt in which the extracellular ligand binding portion of the human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG1.
- TNFR Fc
- Fc formulation means a formulation containing etanercept protein
- This experiment was performed to compare the effects of excipients that inhibit aggregation of TNFR: Fc. Specifically, the experiment is to determine whether the difference in the aggregation phenomenon of TNFR: Fc stored at 50 °C according to the type of excipient. Except for arginine, an aqueous solution prepared by the same formulation as used in Amgen's Enbrel product was added and each excipient was added (final concentration was 25 mg / ml Etanercept, 0.66% w / v sucrose, 65 mM sodium chloride, 17 mM sodium phosphate, hydrogen ion concentration 6.4) The degree of aggregation after storage at 50 °C was compared.
- the final concentration of excipient used in each aqueous solution was 25 mM arginine, 100 mM proline, 80 mM histidine, 100 mM glycine, 0.2 M ammonium chloride, 10 mM EDTA, 20% w / v sucrose, 20% w / v trihalose , 10% w / v polyethylene glycol, 0.04% w / v polysorbate 20, 0.1% w / v hydroxypropylcyclodextrin, and the degree of aggregation of TNFR: Fc was measured using SEC-HPLC.
- Protein was injected into TSK-gel G3000SWXL (7.8 X 300 mm) HPLC column (TOSOH, Japan) under buffer mobile phase conditions of 50 mM sodium phosphate (pH 6.8), 0.15 M sodium chloride, 0.05% w / v sodium azide and 280 Protein peaks were detected at nm.
- polysorbate 20 as a surfactant component, hydroxypropylcyclodextrin, amphiphilic polymer polyethylene glycol, EDTA as a metal ion removing agent, arginine as an amino acid-based excipient, proline, histidine, glycine and the like do not inhibit aggregation at all.
- sucrose and trihalose which are sugar-based excipients, had better anti-agglomeration effects than other excipients.
- almost all TNFR: Fc was aggregated, whereas only about 50% of the protein was changed to the aggregated form when ammonium chloride was used as the excipient.
- this experiment was performed using TNFR: Fc. This experiment was performed to compare the degree of aggregation when arginine, an excipient used to inhibit aggregation of TNFR: Fc, and other excipients were used.
- Excipients selected for comparison are proline, ammonium chloride, sucrose, polysorbate 20 and hydroxypropylcyclodextrin.
- a negative control except for arginine at a final concentration of 10 mg / ml TNFR: Fc, 1% w / v sucrose, 100 mM sodium chloride, 25 mM sodium phosphate, hydrogen ion concentration of 6.4, and a positive control containing 25 mM arginine were prepared.
- the excipients were replaced with 100 mM proline, 50-200 mM ammonium chloride, 20% w / v sucrose, 0.04% w / v polysorbate 20, and 0.1% w / v hydroxypropylcyclodextrin, respectively. Each was tested. Each formulation was stored at 50 ° C. for 1 week in the same manner as in Example 1. SEC-HPLC was used in the same manner as in Example 1 to determine the aggregation phenomenon.
- the experiment was performed by modifying the experiment temperature to 37 °C in order to further demonstrate the aggregation inhibitory effect of the ammonium chloride excipient proved to be effective at high temperature.
- This experiment was carried out to demonstrate the effect of inhibiting aggregation by the combination of ammonium sulfate, an ammonium salt other than ammonium chloride, with other excipients generally known to be capable of inhibiting protein aggregation.
- the final concentration was 4 weeks at 37 ° C.
- Stabilizing buffer composition without excipients for suppressing aggregation negative control
- formulation with 25 mM arginine positive control
- Formulations containing lysine were used. Each formulation was stored at 37 ° C. for 4 weeks. The aggregation inhibitory effect was observed using SEC-HPLC as in Example 1.
- TNFR Fc in combination with ammonium chloride and ammonium sulfate, and other excipients generally known to have protein aggregation inhibitory effects.
- Agglutination inhibitory effects of ammonium salts were observed in formulation solutions of 50 mg / ml TNFR: Fc stored at 45 ° C. under 1% w / v sucrose, 100 mM sodium chloride, 25 mM sodium phosphate, and stabilization buffer at pH 6.4. It was.
- Stabilization buffer composition without agglutination inhibitor negative control
- formulation containing arginine at a final concentration of 25 mM positive control
- formulation containing 12.5 mM, 25 mM, 50 mM respectively, at a final concentration of ammonium chloride
- 25 Formulations containing mM ammonium sulfate, 25 mM ammonium chloride and 25 mM lysine or 5% w / v sucrose formulations containing 50 mM ammonium chloride and 25 mM lysine or 5% w / v sucrose
- the aggregation inhibitory effect was observed using SEC-HPLC as in Example 1.
- composition containing ammonium salts or ammonium salts and succinate salts according to the present invention effectively inhibits the aggregation of Fc-fusion proteins, and thus enables long-term storage of the fusion proteins, and thus are widely used in the medical field using Fc-fusion proteins. Can be used.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Materials Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
% Aggregation | ||||
Week | 0 | 1 | 2 | 4 |
Control | 0.3 | 1.3 | 1.4 | 3.1 |
Arg | 1.1 | 1.4 | 3.1 | |
AmCl | 1.1 | 13.3 | 2.7 | |
AmSul | 1.0 | 1.3 | 2.7 | |
Am+Lys | 0.9 | 1.3 | 2.4 | |
Am+EDTA | 1.6 | 2.8 | 5.2 | |
Am+Tween | 1.6 | 2.7 | 4.9 | |
Am+Sucrose | 1.0 | 1.2 | 2.4 |
% Aggregation | ||||
Day | 0 | 3 | 7 | 14 |
Control | 0.9 | 2.2 | 3.7 | 4.6 |
Arg | 1.9 | 3.2 | 3.8 | |
AmCl 12.5 | 2.3 | 3.5 | 4.4 | |
AmCl 25 | 2.1 | 3.2 | 4.0 | |
AmCl 50 | 1.8 | 3.0 | 3.7 | |
AmSul | 1.7 | 3.0 | 3.6 | |
Am25+Lys | 1.7 | 2.8 | 3.5 | |
Am25+Suc | 1.6 | 2.9 | 3.5 | |
Am50+Lys | 1.5 | 2.6 | 3.0 | |
Am50+Suc | 1.8 | 2.6 | 3.1 |
Claims (32)
- 암모늄염을 함유하는, 단백질과 Fc 도메인의 융합 단백질의 안정화용 조성물.
- 제1항에 있어서, 숙신산염(succinate)를 추가로 포함하는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질의 안정화용 조성물.
- 제2항에 있어서, 상기 숙신산염은 5 내지 200 mM 농도로 포함되는 것을 특징으로 하는융합 단백질의 안정화용 조성물.
- 제2항 또는 제3항에 있어서, 숙신산염은 pH는 5.5 내지 6.5의 완충액 역할을 수행하는 것을 특징으로 하는융합 단백질의 안정화용 조성물.
- 제1항에 있어서, 상기 암모늄염은 단백질과 Fc 도메인의 융합 단백질의 응집을 억제하는 것을 특징으로 하는융합 단백질의 안정화용 조성물.
- 제1항에 있어서, 상기 암모늄염은 염화암모늄, 황산암모늄, 탄산암모늄 및 질산암모늄 중에서 선택되는 것을 특징으로 하는융합 단백질의 안정화용 조성물.
- 제1항에 있어서, 상기 암모늄염은 5 내지 500 mM의 농도로 함유되는 것을 특징으로 하는융합 단백질의 안정화용 조성물.
- 제1항에 있어서, 상기 융합 단백질은 인간 p75 종양괴사인자 수용체의 세포외 리간드 결합부가 인간 IgG1의 Fc 도메인에 융합된 것을 특징으로 하는융합 단백질의 안정화용 조성물.
- 제1항에 있어서, 상기 안정화용 조성물은 부형제를 추가로 함유하는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질의 안정화용 조성물.
- 제9항에 있어서, 상기 부형제는 염기성 아미노산, 당 및 계면활성제 중에서 선택되는 1종 이상인 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질의 안정화용 조성물.
- 제9항에 있어서, 상기 부형제는 수크로오스 또는 라이신, 또는 둘 다 인것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질의 안정화용 조성물.
- 단백질과 Fc 도메인의 융합 단백질을 함유하는 조성물에 암모늄염을 가하여 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제12항에 있어서, 상기 조성물은 숙신산염을 추가로 포함하는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제13항에 있어서, 상기 숙신산염은 5 내지 200 mM 농도로 포함되는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제13항 또는 제14항에 있어서, 숙신산염은 pH는 5.5 내지 6.5의 완충액 형태로 첨가되는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제12항에 있어서, 상기 암모늄염은 단백질과 Fc 도메인의 융합 단백질의 응집을 억제하는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제12항에 있어서, 상기 암모늄염은 염화암모늄, 황산암모늄, 탄산암모늄 및 질산암모늄 중에서 선택되는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제12항에 있어서, 상기 암모늄염은 5 내지 500 mM의 농도로 함유되는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제12항에 있어서, 상기 융합 단백질은 인간 p75 종양괴사인자 수용체의 세포외 리간드 결합부가 인간 IgG1의 Fc 도메인에 융합된 것인 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제12항에 있어서, 상기 안정화용 조성물은 부형제를 추가로 함유하는 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제20항에 있어서, 상기 부형제는 염기성 아미노산, 당 및 계면활성제 중에서 선택되는 1종 이상인 것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 제21항에 있어서, 상기 부형제는 수크로오스 또는 라이신, 또는 둘 다 인것을 특징으로 하는 단백질과 Fc 도메인의 융합 단백질을 안정화시키는 방법.
- 인간 p75 종양괴사인자 수용체의 세포외 리간드 결합부가 인간 IgG1의 Fc 도메인에 융합된 융합 단백질과 암모늄염을 함유하는 관절염 치료용 조성물.
- 제23항에 있어서, 숙신산염을 추가로 포함하는 것을 특징으로 하는 관절염 치료용 조성물.
- 제24항에 있어서, 상기 숙신산염은 5 내지 200 mM 농도로 포함되는 것을 특징으로 하는 관절염 치료용 조성물.
- 제24항 또는 제25항에 있어서, 숙신산염은 pH는 5.5 내지 6.5의 완충액 형태로 첨가되는 것을 특징으로 하는 관절염 치료용 조성물.
- 제23항에 있어서, 상기 암모늄염은 단백질과 Fc 도메인의 융합 단백질의 응집을 억제하는 것을 특징으로 하는 관절염 치료용 조성물.
- 제23항에 있어서, 상기 암모늄염은 염화암모늄, 황산암모늄, 탄산암모늄 및 질산암모늄 중에서 선택되는 것을 특징으로 하는 관절염 치료용 조성물.
- 제23항에 있어서, 상기 암모늄염은 5 내지 500 mM의 농도로 함유되는 것을 특징으로 하는 관절염 치료용 조성물.
- 제23항에 있어서, 상기 조성물은 부형제를 추가로 함유하는 것을 특징으로 하는 관절염 치료용 조성물.
- 제30항에 있어서, 상기 부형제는 염기성 아미노산, 당 및 계면활성제 중에서 선택되는 1종 이상인 것을 특징으로 하는 관절염 치료용 조성물.
- 제30항에 있어서, 상기 부형제는 수크로오스 또는 라이신, 또는 둘 다 인것을 특징으로 하는 관절염 치료용 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380065765.7A CN104870019A (zh) | 2012-11-27 | 2013-10-23 | 用于稳定蛋白质和Fc结构域融合的融合蛋白的组合物 |
US14/439,644 US9474803B2 (en) | 2012-11-27 | 2013-10-23 | Composition for stabilizing fusion protein in which protein and FC domain are fused |
EP13857947.9A EP2926834A4 (en) | 2012-11-27 | 2013-10-23 | COMPOSITION FOR STABILIZING A FUSION PROTEIN IN WHICH A PROTEIN AND A DOMAIN FC ARE MERGED |
JP2015542943A JP6026002B2 (ja) | 2012-11-27 | 2013-10-23 | タンパク質とFcドメインを融合した融合タンパク質の安定化用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0134946 | 2012-11-27 | ||
KR20120134946 | 2012-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014084508A1 true WO2014084508A1 (ko) | 2014-06-05 |
Family
ID=50828096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/009474 WO2014084508A1 (ko) | 2012-11-27 | 2013-10-23 | 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9474803B2 (ko) |
EP (1) | EP2926834A4 (ko) |
JP (1) | JP6026002B2 (ko) |
KR (1) | KR101419884B1 (ko) |
CN (1) | CN104870019A (ko) |
WO (1) | WO2014084508A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA012801B1 (ru) | 2005-06-14 | 2009-12-30 | Эмджен Инк. | Самобуферирующиеся композиции белков |
WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
US9821059B2 (en) * | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
EP3484520A4 (en) | 2016-07-13 | 2020-07-29 | Reform Biologics, LLC | STABILIZING EXCIPIENTS FOR THERAPEUTIC PROTEIN FORMULATIONS |
EP3528787A4 (en) * | 2016-10-21 | 2020-05-06 | Amgen Inc. | PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION |
US11236146B2 (en) | 2016-10-28 | 2022-02-01 | Celltrion Inc. | Stable pharmaceutical formulation |
WO2019036619A1 (en) * | 2017-08-18 | 2019-02-21 | Reform Biologics, Llc | STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN |
EP3679945A4 (en) | 2017-09-07 | 2021-06-16 | JCR Pharmaceuticals Co., Ltd. | AQUEOUS PHARMACEUTICAL COMPOSITION |
CA3081094A1 (en) * | 2017-11-20 | 2019-05-23 | Alison J. GILLESPIE | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
GB201901547D0 (en) * | 2019-02-05 | 2019-03-27 | Arecor Ltd | Stabilized Fc Fusion protein solutions |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4362661A (en) | 1979-08-09 | 1982-12-07 | Teijin Limited | Immunoglobulin composition having a high monomer content, and process for production thereof |
US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
US7648702B2 (en) | 2002-02-27 | 2010-01-19 | Immunex Corporation | Stable aqueous formulation of a soluble TNF receptor and arginine |
US20100254985A1 (en) | 2006-02-03 | 2010-10-07 | Medimmune, Llc | Protein Formulations |
US20120116057A1 (en) * | 2009-07-08 | 2012-05-10 | Amgen Inc. | Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering |
WO2012143418A1 (en) * | 2011-04-20 | 2012-10-26 | Sandoz Ag | STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc |
WO2013006454A1 (en) * | 2011-07-01 | 2013-01-10 | Biogen Idec Ma Inc. | Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US5464934A (en) | 1993-05-14 | 1995-11-07 | Mallinckrodt Medical, Inc. | Metal chelates as spacer compounds in biologically active peptides |
PT1324776E (pt) * | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
WO2003000014A2 (en) | 2001-06-21 | 2003-01-03 | Altus Biologics, Inc. | Spherical protein particles and methods of making and using them |
CA2528591C (en) | 2003-06-12 | 2013-01-08 | Eli Lilly And Company | Glp-1 analog fusion proteins |
WO2005012353A1 (en) | 2003-08-01 | 2005-02-10 | Amgen Inc. | Crystalline tumor necrosis factor receptor 2 polypeptides |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
US8216575B2 (en) * | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
KR20150067395A (ko) | 2006-12-01 | 2015-06-17 | 메다렉스, 엘.엘.시. | 씨디22에 결합하는 인간 항체 및 이의 용도 |
CN105198998A (zh) | 2007-05-30 | 2015-12-30 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
AU2008314689A1 (en) | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an Fc-containing protein |
PE20120359A1 (es) | 2009-03-06 | 2012-04-13 | Genentech Inc | Formulacion con anticuerpo |
ES2684921T3 (es) | 2010-05-10 | 2018-10-05 | Intas Pharmaceuticals Limited | Formulación líquida de polipéptidos que contienen un dominio Fc de una inmunoglobulina |
-
2013
- 2013-10-23 JP JP2015542943A patent/JP6026002B2/ja not_active Expired - Fee Related
- 2013-10-23 CN CN201380065765.7A patent/CN104870019A/zh active Pending
- 2013-10-23 WO PCT/KR2013/009474 patent/WO2014084508A1/ko active Application Filing
- 2013-10-23 EP EP13857947.9A patent/EP2926834A4/en not_active Withdrawn
- 2013-10-23 US US14/439,644 patent/US9474803B2/en active Active
- 2013-10-23 KR KR1020130126295A patent/KR101419884B1/ko active IP Right Grant
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4362661A (en) | 1979-08-09 | 1982-12-07 | Teijin Limited | Immunoglobulin composition having a high monomer content, and process for production thereof |
US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
US7648702B2 (en) | 2002-02-27 | 2010-01-19 | Immunex Corporation | Stable aqueous formulation of a soluble TNF receptor and arginine |
US20100254985A1 (en) | 2006-02-03 | 2010-10-07 | Medimmune, Llc | Protein Formulations |
US20120116057A1 (en) * | 2009-07-08 | 2012-05-10 | Amgen Inc. | Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering |
WO2012143418A1 (en) * | 2011-04-20 | 2012-10-26 | Sandoz Ag | STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc |
WO2013006454A1 (en) * | 2011-07-01 | 2013-01-10 | Biogen Idec Ma Inc. | Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use |
Non-Patent Citations (6)
Title |
---|
"Current Trends in Monoclonal Antibody Development and Manufacturing", BIOTECHNOLOGY: PHARMACEUTICAL ASPECTS, vol. XI, 2010, pages 271 - 291 |
CHUNG, H.S. ET AL., REGULATORY PEPTIDE, vol. 170, 2011 |
HAMADA, H. ET AL., CURRENT PHARMACEUTICAL BIOTECHNOLOGY, vol. 10, 2009, pages 348 |
HAMADA, H. ET AL., CURRENT PHARMACEUTICAL BIOTECHNOLOGY, vol. 10, 2009, pages 400 |
KUNZ, W. ET AL., CURR. OPIN. COLL. INTERFACE SCI., vol. 9, 2004, pages 1937 |
STEVEN J. SHIRE ET AL.: "Biotechnology: Pharmaceutical Aspects", CURRENT TRENDS IN MONOCLONAL ANTIBODY DEVELOPMENT AND MANUFACTURING, vol. XI, 2010, pages 115 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
Also Published As
Publication number | Publication date |
---|---|
JP2016502528A (ja) | 2016-01-28 |
JP6026002B2 (ja) | 2016-11-16 |
US20150313996A1 (en) | 2015-11-05 |
EP2926834A4 (en) | 2016-04-20 |
EP2926834A1 (en) | 2015-10-07 |
CN104870019A (zh) | 2015-08-26 |
US9474803B2 (en) | 2016-10-25 |
KR20140067897A (ko) | 2014-06-05 |
KR101419884B1 (ko) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014084508A1 (ko) | 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 | |
US9453067B2 (en) | Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc | |
EP2568960B1 (en) | Liquid formulation of polypeptides containing an fc domain of an immunoglobulin | |
CA2476934C (en) | Stabilized tnfr-fc composition comprising arginine | |
KR101335765B1 (ko) | 지속형 에리스로포이에틴 결합체의 액상 제제 | |
KR102061355B1 (ko) | 아르기닌-없는 tnfr : fc-융합 폴리펩티드 조성물 및 이용 방법 | |
WO2012165917A1 (en) | Stable liquid formulation of etanercept | |
WO2011090305A2 (en) | Liquid formulations for long-acting g-csf conjugate | |
TW201410704A (zh) | 長效胰島素及胰促泌素肽之液體製劑 | |
WO2020055123A1 (ko) | 단백질을 포함하는 액상 조성물 | |
KR20060089227A (ko) | 항체의 안정화 방법 및 안정화된 용액상 항체 제제 | |
JP7442595B2 (ja) | ミオスタチンに結合するフィブロネクチンベースの足場ドメインタンパク質の安定製剤 | |
WO2018131893A1 (ko) | 안정한 액체 제제 | |
US20190298836A1 (en) | Dissolvable films and methods of their use | |
WO2019124946A1 (ko) | Vegf 길항제를 포함하는 액상 조성물 | |
WO2024087834A1 (zh) | 生长激素fc融合蛋白注射液及其用途 | |
WO2017116191A2 (ko) | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 | |
WO2018080196A2 (ko) | 안정한 약제학적 제제 | |
NZ620160B2 (en) | Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13857947 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14439644 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015542943 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013857947 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |